{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=100+mg",
    "query": {
      "intervention": "100 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 5807,
    "total_pages": 581,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=100+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T09:52:22.767Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04018248",
      "title": "BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma",
        "Follicular Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Leukemia",
        "B Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Waldenstrom Macroglobulinemia",
        "Peripheral T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "BR101801 (Phase Ia)",
          "type": "DRUG"
        },
        {
          "name": "BR101801 (Phase Ib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boryung Pharmaceutical Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2020-04-21",
      "completion_date": "2023-09-21",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04018248"
    },
    {
      "nct_id": "NCT03320174",
      "title": "Long-Term Safety Study of Tafenoquine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Tafenoquine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "60 Degrees Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 600,
      "start_date": "2017-10-05",
      "completion_date": "2021-07-13",
      "has_results": true,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 2,
      "location_summary": "Colorado Springs, Colorado • McAllen, Texas",
      "locations": [
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03320174"
    },
    {
      "nct_id": "NCT01345318",
      "title": "B0151005 Open-Label Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "PF-04236921",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 191,
      "start_date": "2011-06",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2024-01-12",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 62,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Lakewood, Colorado + 30 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01345318"
    },
    {
      "nct_id": "NCT02369523",
      "title": "Multimodal Pain Management Following Primary TKA",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "Exparel",
          "type": "DRUG"
        },
        {
          "name": "Ropivacaine cocktail (PIC)",
          "type": "DRUG"
        },
        {
          "name": "Bupivacaine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 84,
      "start_date": "2014-09",
      "completion_date": "2017-04",
      "has_results": false,
      "last_update_posted_date": "2023-08-15",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02369523"
    },
    {
      "nct_id": "NCT04373317",
      "title": "Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Parkinson's Disease Psychosis"
      ],
      "interventions": [
        {
          "name": "Pimavanserin",
          "type": "DRUG"
        },
        {
          "name": "Quetiapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 358,
      "start_date": "2022-10-24",
      "completion_date": "2028-08-24",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04373317"
    },
    {
      "nct_id": "NCT01337089",
      "title": "Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "Nabiximols",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 660,
      "start_date": "2011-01-19",
      "completion_date": "2016-01-27",
      "has_results": true,
      "last_update_posted_date": "2023-04-12",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • El Cajon, California • Gilroy, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "El Cajon",
          "state": "California"
        },
        {
          "city": "Gilroy",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01337089"
    },
    {
      "nct_id": "NCT00481091",
      "title": "A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "ABT-263",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2007-07-25",
      "completion_date": "2022-05-12",
      "has_results": true,
      "last_update_posted_date": "2023-06-13",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Boston, Massachusetts • Omaha, Nebraska + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00481091"
    },
    {
      "nct_id": "NCT00983424",
      "title": "Cyclosporine A in Combination With Nab-Paclitaxel in Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclosporins",
          "type": "DRUG"
        },
        {
          "name": "nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2010-02",
      "completion_date": "2013-05",
      "has_results": false,
      "last_update_posted_date": "2013-09-16",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983424"
    },
    {
      "nct_id": "NCT01117623",
      "title": "Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm"
      ],
      "interventions": [
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg",
          "type": "DRUG"
        },
        {
          "name": "Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg",
          "type": "DRUG"
        },
        {
          "name": "HCC Child-Pugh A expansion cohort: Regorafenib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "HCC Child-Pugh B expansion cohort: Regorafenib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "NSCLC expansion cohort: Regorafenib 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2007-02",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2015-11-18",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01117623"
    },
    {
      "nct_id": "NCT01560143",
      "title": "Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Tigecycline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Manjunath Prakash Pai",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 12,
      "start_date": "2012-03",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2017-02-09",
      "last_synced_at": "2026-09-03T09:52:22.767Z",
      "location_count": 1,
      "location_summary": "Albany, New York",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01560143"
    }
  ]
}